We're experimenting and would love to hear from you!
In this episode of Discover Daily, we begin with Meta's Orion AR glasses prototype, which uses silicon carbide lenses and a neural wristband for intuitive control. These lightweight glasses project holograms onto the real world, offering a 70-degree field of view and gesture controls. While still in development, Orion represents a significant step towards Meta's vision of AR as the future of personal computing.
We also delve into OpenAI's controversial shift from a nonprofit to a for-profit model, potentially valuing the company at $150 billion. This move has sparked debates about AI ethics and development priorities, with critics like Elon Musk calling it "illegal." The restructuring aims to attract investors and compete with tech giants, but raises questions about OpenAI's commitment to its original mission of developing beneficial AI.
Our deep dive focuses on the discovery of the MAL blood group system, solving a 50-year mystery in hematology. This rare blood type, characterized by the absence of the AnWj antigen, has significant implications for transfusion medicine and patient care. The discovery opens new avenues for research in genetic screening, antigen development, and personalized medicine, potentially leading to improved transfusion safety and novel therapeutic approaches.
From Perplexity's Discover Feed:
https://www.perplexity.ai/page/meta-s-orion-ar-glasses-PgiV4ahWRR2FUrtReWqGZQ
https://www.perplexity.ai/page/openai-s-for-profit-pivot-Mg7ldRffSXme1JG83ig7lQ
https://www.perplexity.ai/page/new-blood-group-identified-LEhLeJENRHSrdAPRtKwUjA
Perplexity is the fastest and most powerful way to search the web. Perplexity crawls the web and curates the most relevant and up-to-date sources (from academic papers to Reddit threads) to create the perfect response to any question or topic you’re interested in.
Take the world's knowledge with you anywhere. Available on iOS and Android
Join our growing Discord community for the latest updates and exclusive content.
Follow us on:
